C. Porta

Oncology · New England Journal of Medicine · 2008–2021

A researcher in the Science corpus: 11 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom C. Porta trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. J. Stockman
  2. Hongbo Chi
  3. B. Leibovich
  4. R. Shaw
  5. N. Hay
  6. M. Laplante
  7. Jiyong Liang
  8. J. Testa
  9. Tony Pawson

Papers from C. Porta's perspective

Ordered by how strongly the researchers C. Porta trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. (New England Journal of Medicine)
  2. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. (Journal of Clinical Oncology)
  3. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer (Nature Medicine)
  4. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing (New England Journal of Medicine)
  5. Correcting for non-compliance in randomized trials using rank preserving structural failure time models
  6. Improved prognostication of renal cell carcinoma using an integrated staging system. (Journal of Clinical Oncology)
  7. The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters (American Journal of Surgical Pathology)
  8. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study (The Lancet Oncology)
  9. The somatic genomic landscape of chromophobe renal cell carcinoma (Cancer Cell)
  10. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. (European Urology)

Their papers